KALA BIO (NASDAQ:KALA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of KALA BIO (NASDAQ:KALA) in a research note published on Friday,Benzinga reports. They currently have a $15.00 price objective on the stock.

Separately, Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a report on Monday, August 19th.

KALA BIO Trading Down 0.9 %

Shares of NASDAQ:KALA opened at $6.70 on Friday. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 3.07. The company’s 50-day moving average price is $6.02 and its two-hundred day moving average price is $6.28. The stock has a market capitalization of $30.89 million, a PE ratio of -0.54 and a beta of -2.13. KALA BIO has a one year low of $4.21 and a one year high of $10.97.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. On average, equities analysts forecast that KALA BIO will post -11.01 EPS for the current fiscal year.

Institutional Trading of KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP bought a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up about 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th biggest position. SR One Capital Management LP owned 15.76% of KALA BIO as of its most recent SEC filing. Institutional investors own 24.61% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.